Determination of HLA‐A, ‐C, ‐B, ‐DRB1 allele and haplotype frequency in Japanese population based on family study

Ikeda, Natsumi; Kojima, Hiroto; Nishikawa, Masanori; Hayashi, Kosuke; Futagami, Takaomi; Tsujino, Takeshi; Kusunoki, Yoichiro; Fujii, Norihiko; Suegami, Shinji; Miyazaki, Yuki; Middleton, Derek; Tanaka, Hidenori; Saji, Hiroh

doi:10.1111/tan.12536

Cited by 144 publications

(153 citation statements)

References 31 publications

Supporting

Mentioning

136

Contrasting

Order By: Relevance

“…Recent report showed 92% of HLA-B27 positive ReA patients developed SpA compared with 10% of HLA-B27 negative patients in the 2002-2012 cohort [11]. This might indicate that no progression to SpA in iBCG-induced ReA patients in the present study might be caused by the low rate (0.3%) of positivity for HLA-B27 in the Japanese population [12]. This study has several limitations.…”

Section: Brief Reportcontrasting

confidence: 45%

Trend of Frequency and Outcome of Reactive Arthritis in Japanese Patients with Bladder Cancer following Intravesical BCG Therapy over the Last 20 Years

Taniguchi¹,

Nishikawa²,

Yoshinaga³

et al. 2018

J Rheum Dis Treat

View full text Add to dashboard Cite

Reactive arthritis (ReA) is a sterile arthritis occurring in a genetically predisposed individual, secondary to an extra-articular infection, usually of the gastrointestinal or genitourinary tract. Intravesical instillation of Bacillus Calmette-Guerin (iBCG) is used as an effective immunotherapy of bladder cancer. Despite of the clinical efficacy, ReA could develop as adverse event and the frequencies are known as about 0.5 to 1% in Western countries and 2.0% in Japan. However, the trend of frequency and outcome of iBCG-induced ReA in Japanese patients have not been assessed in multi-centre studies. Herein, Japanese patients who received iBCG (n = 555) for bladder cancer from March 1997 to February 2017 were retrospectively assessed. Of the 555 cases, ReA was revealed in 11/555 (2.0%). Although the protocol of iBCG therapy was not statistically different over the 20 years, but a half dose of iBCG was used in 2007 to 2017 more than in 1997 to 2007. Despite the increase of the use of half dose of iBCG in 2007 to 2017, the overall frequency of iBCG-induced ReA was not significantly different between from 1997 to 2007 and from 2007 to 2017 (2.1% and 1.9%, respectively). This suggests that the development of iBCG-induced ReA was dose-independent. Furthermore, all iBCG-induced ReA, even if revealing sacroiliitis, did not progress to chronic peripheral arthritis type and spondyloarthritis over the last 20 years.

show abstract

Section: Brief Reportcontrasting

confidence: 45%

Trend of Frequency and Outcome of Reactive Arthritis in Japanese Patients with Bladder Cancer following Intravesical BCG Therapy over the Last 20 Years

Taniguchi¹,

Nishikawa²,

Yoshinaga³

et al. 2018

J Rheum Dis Treat

View full text Add to dashboard Cite

show abstract

“…Recently, immunoepitopes targeted by HLA-restricted T cells were identified in the early viral gene region of BK polyomavirus (38). Interestingly, a prediction of immunoepitopes (http://www.syfpeithi.de/bin/MHCServer.dll/EpitopePrediction.htm) identified the V392 in TAg of JCV as an immunodominant epitope with a top 20 score for HLA-A02 and -A24 nonamers, which are major HLA types in members of the Japanese population (39). It is possible that targeting by T cells might be associated with the occurrence of the common mutation in the JCV genome among patients with PML.…”

Section: Discussionmentioning

confidence: 99%

Deep-Sequence Identification and Role in Virus Replication of a JC Virus Quasispecies in Patients with Progressive Multifocal Leukoencephalopathy

Takahashi

Sekizuka

Fukumoto

et al. 2017

J Virol

View full text Add to dashboard Cite

JC virus (JCV) is a DNA virus causing progressive multifocal leukoencephalopathy (PML) in immunodeficient patients. In the present study, 22 genetic quasispecies with more than 1.5% variant frequency were detected in JCV genomes from six clinical samples of PML by next-generation sequencing. A mutation from A to C at nucleotide (nt) 3495 in JCV Mad1 resulting in a V-to-G amino acid substitution at amino acid (aa) position 392 of the large T antigen (TAg) was identified in all six cases of PML at 3% to 19% variant frequencies. Transfection of JCV Mad1 DNA possessing the V392G substitution in TAg into IMR-32 and human embryonic kidney 293 (HEK293) cells resulted in dramatically decreased production of JCV-encoded proteins. The virus DNA copy number was also reduced in supernatants of the mutant virus-transfected cells. Transfection of the IMR-32 and HEK293 cells with a virus genome containing a revertant mutation recovered viral production and protein expression. Cotransfection with equal amounts of wild-type genome and mutated JCV genome did not reduce the expression of viral proteins or viral replication, suggesting that the mutation did not have any dominantnegative function. Finally, immunohistochemistry demonstrated that TAg was expressed in all six pathological samples in which the quasispecies were detected. In conclusion, the V392G amino acid substitution in TAg identified frequently in PML lesions has a function in suppressing JCV replication, but the frequency of the mutation was restricted and its role in PML lesions was limited.IMPORTANCE DNA viruses generally have lower mutation frequency than RNA viruses, and the detection of quasispecies in JCV has rarely been reported. In the present study, a next-generation sequencer identified a JCV quasispecies with an amino acid substitution in the T antigen in patients with PML. In vitro studies showed that the mutation strongly repressed the expression of JC viral proteins and reduced the viral replication. However, because the frequency of the mutation was low in each case, the total expression of virus proteins was sustained in vivo. Thus, JC virus replicates in PML lesions in the presence of a mutant virus which is able to repress virus replication.

show abstract

“…Secondly, HLA-B*51:01 demonstrated strong positive LD with HLA-C*14:02 among Japanese. 21 In the present analysis, 98% of patients with HLA-C*14:02 (843 of 860) were HLA-B*51:01-positive; therefore, the patient HLA-C*14:02-B*51:01 haplotype showed a similar effect in increasing the risk of grades III-IV acute GvHD (HR, 1.37; 95%CI: 1.17-1.60; P<0.001) and mortality (HR, 1.18; 95%CI: 1.07-1.31; P<0.001) as patient HLA-C*14:02 (Table 2). Among HLA-B*51:01-positive patients (n=1058), 843 patients (80%) had HLA-C*14:02, while 215 patients had HLA-C alleles other than HLA-C*14:02.…”

Section: Hla-c*14:02 and -B*51:01 Were In Strong Linkage Disequilibriummentioning

confidence: 99%

High-risk HLA alleles for severe acute graft- versus -host disease and mortality in unrelated donor bone marrow transplantation

et al. 2016

View full text Add to dashboard Cite

Determination of HLA‐A, ‐C, ‐B, ‐DRB1 allele and haplotype frequency in Japanese population based on family study

Cited by 144 publications

References 31 publications

Trend of Frequency and Outcome of Reactive Arthritis in Japanese Patients with Bladder Cancer following Intravesical BCG Therapy over the Last 20 Years

Trend of Frequency and Outcome of Reactive Arthritis in Japanese Patients with Bladder Cancer following Intravesical BCG Therapy over the Last 20 Years

Deep-Sequence Identification and Role in Virus Replication of a JC Virus Quasispecies in Patients with Progressive Multifocal Leukoencephalopathy

High-risk HLA alleles for severe acute graft- versus -host disease and mortality in unrelated donor bone marrow transplantation

Contact Info

Product

Resources

About